Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab for Acute GVHD Prophylaxis in AML/MDS
NCT02737306Phase 2Terminated
- Sponsor
- CytoDyn Inc.
- Start
- May 2017
- Primary completion
- Apr 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of leronlimab in graft-versus-host disease (GVHD), sponsored by CytoDyn Inc.. Started May 2017; status: terminated.
02
Drugs
leronlimab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02737306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737306.